MOTIVATE Course 3: Prevention of MOH
1 CPD points with the RACGP
|
1 Educational activity hour with the ACRRM
|
All participants will be awarded a certificate of completion for self-reporting to other colleges
Duration: 30 minutes
Treatment of MOH may be difficult, and so it is important for patients to understand how to prevent this condition in the first place. As a healthcare professional, learn how to recognise patients at risk of MOH and educate them on how to avoid falling into the cyclical trap of overusing their headache medications.
Learning objectives:
Upon completing this course, participants will be able to:
- List the classes of medications used to prevent chronic migraine;
- Differentiate treatment for infrequent severe headaches and frequent episodic headaches;
- Outline a plan to address the most common barriers to managing MOH and codeine-withdrawal effects;
- Explain the interdisciplinary (between GPs and pharmacists) management of MOH;
- Put a reminder system in place that would make use of the different monitoring strategies (e.g. headache diaries, support from both GPs and pharmacists, use of clinical measures of headache-related disability) to assess patient compliance to preventive treatment.
- Associate Professor Richard Stark, Alfred Hospital, Melbourne, Victoria
- Professor Mieke Van Driel, School of Medicine, University of Queensland, Herston, Queensland
- Associate Professor Treasure McGuire, School of Pharmacy, University of Queensland, Queensland; Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland
- Dr Brett McFarlane, The Australian College of Pharmacy, Canberra, Australian Capital Territory
- Professor Deborah Turnbull, School of Psychology, University of Adelaide, South Australia
- Royal Australian College of General Practitioners:
- Pending accreditation
- Australian College of Rural and Remote Medicine:1 Core PDP point
- Pending accreditation
- Pharmacists and nurses are invited to access this continuing professional development activity. At the end, a certificate may be downloaded as proof of completion.
Professor Mieke van Driel
The University of Queensland
- Faculty
- Associate Professor Richard Stark: Co-authored a clinical paper sponsored by Pfizer on the safety of eletriptan. Between 2012 and 2014 received consulting and lecture fees from Allergan and lecture fees from MSD on chronic migraine
- Professor Mieke Van Driel: No conflict of interest
- Associate Professor Treasure McGuire: No conflict of interest
- Dr Brett McFarlane: No conflict of interest
- Professor Deborah Turnbull: Received research grants and co-authored papers on hypertension sponsored by pharmaceutical companies, including Pfizer Pty. Ltd., between 1999 and 2006
- GP reviewer
- Professor Mieke Van Driel: No conflict of interest
- Non-faculty: employees of In Vivo Academy involved in producing the content of this course, Yulyana, Tina Garcia, Monica Kurniawan and Lisa Sullivan, declare no conflict of interest.
